Q1 EPS Forecast for Pacira BioSciences Lowered by Analyst

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Research analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for shares of Pacira BioSciences in a report released on Wednesday, December 11th. Zacks Research analyst R. Department now expects that the company will earn $0.60 per share for the quarter, down from their previous forecast of $0.61. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Pacira BioSciences' Q3 2025 earnings at $0.54 EPS and Q2 2026 earnings at $0.63 EPS.

A number of other research analysts also recently issued reports on PCRX. HC Wainwright reiterated a "buy" rating and set a $39.00 target price on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Jefferies Financial Group increased their price target on Pacira BioSciences from $15.00 to $18.00 and gave the stock a "buy" rating in a report on Tuesday, September 24th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Pacira BioSciences in a report on Friday, November 8th. Royal Bank of Canada increased their target price on Pacira BioSciences from $15.00 to $16.00 and gave the stock a "sector perform" rating in a report on Thursday, November 7th. Finally, Barclays decreased their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating for the company in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $23.50.

Pacira BioSciences Trading Down 1.2 %

PCRX traded down $0.23 during trading on Friday, hitting $19.57. The company's stock had a trading volume of 295,505 shares, compared to its average volume of 850,650. The firm has a market capitalization of $903.55 million, a P/E ratio of -9.75 and a beta of 0.80. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $35.95. The stock's fifty day moving average price is $17.21 and its 200-day moving average price is $19.18. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Hedge Funds Weigh In On Pacira BioSciences

Several institutional investors have recently modified their holdings of PCRX. Outfitter Financial LLC grew its stake in Pacira BioSciences by 5.7% in the 2nd quarter. Outfitter Financial LLC now owns 20,190 shares of the company's stock valued at $578,000 after purchasing an additional 1,095 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Pacira BioSciences by 6.0% during the second quarter. The Manufacturers Life Insurance Company now owns 23,932 shares of the company's stock worth $685,000 after buying an additional 1,354 shares during the last quarter. nVerses Capital LLC raised its position in Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company's stock worth $51,000 after acquiring an additional 1,600 shares during the period. Innealta Capital LLC bought a new position in shares of Pacira BioSciences during the 2nd quarter valued at approximately $50,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Pacira BioSciences by 0.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 400,002 shares of the company's stock worth $11,444,000 after purchasing an additional 2,141 shares during the period. 99.73% of the stock is owned by institutional investors.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.